The present invention includes a fused polycyclic aromatic compound represented by general formula (1), where in formula (1), one among R.sub.1 and R.sub.2 is represented by general formula (2) and represents a substituent having three to five ring structures, and the other among R.sub.1 and R.sub.2 represents a hydrogen atom, where in formula (2), n represents an integer of 0-2.sub.R. —R.sub.3 represents a divalent linking group obtained by removing two hydrogen atoms from benzene or naphthalene, R.sub.4 represents a divalent linking group obtained by removing two hydrogen atoms from an aromatic ring of an aromatic hydrocarbon, and when n is 2, a plurality of R.sub.4's may be the same as or different from each other, R.sub.5 represents an aromatic hydrocarbon group.

##STR00001##

The present invention includes a fused polycyclic aromatic compound represented by general formula (1), where in formula (1), one among R.sub.1 and R.sub.2 is represented by general formula (2) and represents a substituent having three to five ring structures, and the other among R.sub.1 and R.sub.2 represents a hydrogen atom, where in formula (2), n represents an integer of 0-2.sub.R. —R.sub.3 represents a divalent linking group obtained by removing two hydrogen atoms from benzene or naphthalene, R.sub.4 represents a divalent linking group obtained by removing two hydrogen atoms from an aromatic ring of an aromatic hydrocarbon, and when n is 2, a plurality of R.sub.4's may be the same as or different from each other, R.sub.5 represents an aromatic hydrocarbon group.

##STR00001##

An organic electroluminescence device includes: an anode; a cathode; and an emitting layer provided between the anode and the cathode, in which the emitting layer contains a delayed fluorescent compound M2 and a compound M3 represented by a formula (3) and a singlet energy S.sub.1(M2) of the compound M2 and a singlet energy S.sub.1(M3) of the compound M3 satisfy a relationship of a numerical formula (Numerical Formula 1) below, S.sub.1(M3)>S.sub.1(M2) . . . (Numerical Formula 1). In the formula (3), A3 is a group represented by a formula (3a) or the like.

##STR00001##

Disclosed are a heterocyclic compound represented by Formula 1 and an organic light emitting device using the same. The heterocyclic compound is used as a material for hole injection layer, hole transport layer, hole injection and transport layer, light emission layer, electron transport layer, or electron injection layer of the organic light emitting device and provides improved efficiency, low driving voltage, and improved lifetime characteristic. ##STR00001##

Disclosed are a heterocyclic compound represented by Formula 1 and an organic light emitting device using the same. The heterocyclic compound is used as a material for hole injection layer, hole transport layer, hole injection and transport layer, light emission layer, electron transport layer, or electron injection layer of the organic light emitting device and provides improved efficiency, low driving voltage, and improved lifetime characteristic. ##STR00001##

The present application provides bifunctional compounds of Formula (X): ##STR00001##
or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, which act as protein degradation inducing moieties for protein kinases. The present application also relates to methods for the targeted degradation of one or more protein kinases through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to one or more protein kinases which can be utilized in the treatment of disorders modulated by protein kinases.

The present application provides bifunctional compounds of Formula (X): ##STR00001##
or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, which act as protein degradation inducing moieties for protein kinases. The present application also relates to methods for the targeted degradation of one or more protein kinases through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to one or more protein kinases which can be utilized in the treatment of disorders modulated by protein kinases.

This invention relates to thienopyrimidinones and their use as inhibitors of TRPA1 activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of fibrotic diseases, inflammatory and auto-immune diseases and CNS-related diseases.

This invention relates to thienopyrimidinones and their use as inhibitors of TRPA1 activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of fibrotic diseases, inflammatory and auto-immune diseases and CNS-related diseases.

A compound is represented by Chemical Formula 1. The compound may be included in, a film, an infrared sensor, a combination sensor, and/or an electronic device. ##STR00001## In Chemical Formula 1, X, Y.sup.1, Y.sup.2, Z.sup.1, Z.sup.2, Q, R.sup.1, and R.sup.2 are the same as described in the detailed description.